Selvaraju Veeriah
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Immune responses and vaccinations
- Ferroptosis and cancer prognosis
- Single-cell and spatial transcriptomics
- Mechanisms of cancer metastasis
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- vaccines and immunoinformatics approaches
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Molecular Biology Techniques and Applications
- Immune Cell Function and Interaction
- AI in cancer detection
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Genomics, phytochemicals, and oxidative stress
London Cancer
2014-2025
University College London
2014-2025
Cancer Research UK
2012-2025
CRUK Lung Cancer Centre of Excellence
2017-2025
The Francis Crick Institute
2017-2024
University College London Hospitals NHS Foundation Trust
2020
National Hospital for Neurology and Neurosurgery
2020
Memorial Sloan Kettering Cancer Center
2009-2014
Friedrich Schiller University Jena
2005-2009
University of Würzburg
2007
Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and genome evolution have been limited to small retrospective cohorts. We wanted prospectively investigate in relation clinical outcome determine the clonal nature of driver events evolutionary processes early-stage NSCLC.
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, polymorphic nature locus has precluded accurate HLA copy-number analysis. Here, we heterozygosity in (LOHHLA), computational tool determine allele-specific copy number from sequencing data. Using LOHHLA, find that LOH occurs 40% non-small-cell lung cancers (NSCLCs) and associated with high subclonal neoantigen burden,...
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that expression largely restricted to tumor-infiltrating Treg in mice humans. While existing were observed deplete the periphery, upregulation of inhibitory Fc gamma receptor (FcγR) IIb tumor site prevented intra-tumoral cell depletion, which may underlie lack...
Tyrosine phosphorylation plays a critical role in regulating cellular function and is central feature signaling cascades involved oncogenesis. The regulation of tyrosine coordinately controlled by kinases phosphatases (PTPs). Whereas activation has been shown to play vital roles tumor development, the PTPs much less well defined. Here, we show that receptor protein phosphatase delta (PTPRD) frequently inactivated glioblastoma multiforme (GBM), deadly primary neoplasm brain. PTPRD target...
TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape cancer by tracking clonal heterogeneity and tumour evolution from diagnosis relapse.
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates clinical T receptor (TCR) analysis reveals significantly higher number expanded TCR...
Lung cancer is the leading cause of cancer-associated mortality worldwide
Abstract B cells are frequently found in the margins of solid tumours as organized follicles ectopic lymphoid organs called tertiary structures (TLS) 1,2 . Although TLS have been to correlate with improved patient survival and response immune checkpoint blockade (ICB), underlying mechanisms this association remain elusive Here we investigate lung-resident cell responses patients from TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) other lung cancer cohorts, a...
Metastatic disease is responsible for the majority of cancer-related deaths
Abstract Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance therapy 1 . Here, using paired whole-exome RNA sequencing data, we investigate intratumour transcriptomic diversity in 354 non-small cell tumours from 347 out of the first 421 patients prospectively recruited into TRACERx study 2,3 Analyses 947 tumour regions, representing both primary metastatic disease, alongside 96 tumour-adjacent normal tissue samples implicate transcriptome...
Abstract Murine tissues harbor signature γδ T cell compartments with profound yet differential impacts on carcinogenesis. Conversely, human tissue-resident cells are less well defined. In the present study, we show that lung a resident Vδ1 population. Moreover, demonstrate memory and effector phenotypes were enriched in tumors compared nontumor tissues. Intratumoral possessed stem-like features skewed toward cytolysis helper type 1 function, akin to intratumoral natural killer CD8 +...
Abstract Understanding the role of tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs treatment-naïve early-stage using imaging mass cytometry TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for plasma B immune-excluded squamous cell...
Abstract Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, applications are constrained by the sensitivity of clinically validated ctDNA approaches. NeXT Personal is a whole-genome-based, tumor-informed platform that has been analytically for ultrasensitive at 1–3 ppm with 99.9% specificity. Through an analysis 171 patients lung cancer from TRACERx study, we detected pre-operatively within 81% adenocarcinoma (LUAD), including 53% those...
Abstract Recognition and elimination of pathogens cancer cells depend on the adaptive immune system. Thus, accurate quantification subsets is vital for precision medicine. We present lymphocyte estimation from nucleotide sequencing (ImmuneLENS), which estimates T cell B fractions, class switching clonotype diversity whole-genome data at depths as low 5× coverage. By applying ImmuneLENS to 100,000 Genomes Project, we identify genes enriched with somatic mutations in cell-rich tumors,...